ZyVersa Therapeutics, Inc.
ZVSA
$0.20
$0.014.17%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -72.83% | 6.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -73.77% | 2.94% | |||
| Operating Income | 73.77% | -2.94% | |||
| Income Before Tax | 96.71% | -834.17% | |||
| Income Tax Expenses | 100.00% | -- | |||
| Earnings from Continuing Operations | 96.57% | -795.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 96.57% | -795.65% | |||
| EBIT | 73.77% | -2.94% | |||
| EBITDA | 73.84% | -2.94% | |||
| EPS Basic | 96.74% | -457.07% | |||
| Normalized Basic EPS | 58.32% | 43.50% | |||
| EPS Diluted | 96.74% | -457.07% | |||
| Normalized Diluted EPS | 58.32% | 43.50% | |||
| Average Basic Shares Outstanding | 5.20% | 60.79% | |||
| Average Diluted Shares Outstanding | 5.20% | 60.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||